Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Other Non Operating Income (2016 - 2025)

Theravance Biopharma has reported Other Non Operating Income over the past 12 years, most recently at $3.6 million for Q4 2025.

  • Quarterly Other Non Operating Income rose 302.54% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 108.44% year-over-year, with the annual reading at $10.2 million for FY2025, 108.42% up from the prior year.
  • Other Non Operating Income was $3.6 million for Q4 2025 at Theravance Biopharma, down from $4.1 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $11.6 million in Q4 2022 and troughed at -$375000.0 in Q1 2022.
  • The 5-year median for Other Non Operating Income is $1.4 million (2024), against an average of $2.1 million.
  • Year-over-year, Other Non Operating Income plummeted 113.44% in 2021 and then soared 3325.74% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at $338000.0 in 2021, then soared by 3325.74% to $11.6 million in 2022, then tumbled by 84.05% to $1.8 million in 2023, then tumbled by 51.06% to $904000.0 in 2024, then skyrocketed by 302.54% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Non Operating Income are $3.6 million (Q4 2025), $4.1 million (Q3 2025), and $1.5 million (Q2 2025).